Biosimilar drug development is unique and complex. At PRA, our cross-functional team of experts guide you through the many nuances of the biosimilar landscape and empower you with effective and efficient strategies to bring biosimilars to market. We built a global ecosystem of capabilities and relationships to successfully navigate this landscape. This includes understanding of the quality, analytical, nonclinical and clinical requirements of biosimilars while balancing the need to execute against competitive timelines.
Explore related content and topics
Newsletter
Biosimilars Newsletter Volume 4, October 2014
Welcome to the fourth edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news,…
White Paper
The Value Of Biobetters
The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biologics are expected to account for approximately 17% of total…
Webinar
Biobetters: Challenges and Opportunities
Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars,…